Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: JOHN W. who wrote (2678)	11/7/1997 7:51:00 AM
From: BriBear	Read Replies (1) \| Respond to of 6136

Just received my copy of "Searchlight" the quarterly publication of the AIDS ReSearch Alliance. Good article about cross-resistance (old news, but an excellent summary of issues & resistance testing methods)... healthcg.com Note: "Genotyping" is determining the actual molecular sequence of a gene (or parts thereof) and this article talks about the limitations - specifically, that commercial testing can only look at a certain number of sequences & that sometimes, a mutation in a totally unsuspected region can confer resistance. "Phenotyping" is determing how an organism behaves in a given environment, such as dumping various antivirals into a live culture of HIV & measuring the results - you don't have to know the genetic sequences to determine how the little bastard actually behaves in the "real world". Probably get more useful results, but has (until recently) been difficult to do high-throughput. Also, is anyone watching Affymetrix? They appear to have some very hot genotyping technology....